The study evaluated CAR7 gene therapy in patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL). The so-called basic (gene-editing) modification to create universal "standard" CAR T cells, i.e. cells that are not produced from each patient's own cells, but are prepared in advance. In several patients, these CAR7 T cells induced permanent remissions, in one case the remission lasted for up to 36 months. The therapy was intended for difficult-to-treat patients who failed previous standard treatment. The main result of the study is that even with T‑cell ALL, which is particularly difficult for classic CAR T technologies, it is possible to achieve a long-term disappearance of the disease with the help of genetically modified universal CAR7 cells. The article highlights that this is a promising approach for patients with relapsed or refractory T-cell ALL who otherwise have very limited treatment options.